Page 93 - NobleCon21

Greenwich LifeSciences, Inc.

SELECTED FINANCIAL ITEMS GLSI
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (8.08) (3.28) (4.05) (4.17) (19.59)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (8.04) (3.26) (4.03) (4.15) (19.48)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 4.09 2.75 3.13 3.81 3.81
Cash & Short Term Investments 4.09 2.75 3.13 3.81 3.81
% of Assets 100% 100% 100% 100% 100%
Current Assets -Total 4.09 2.75 3.13 3.81 3.81
% of Assets 100% 100% 100% 100% 100%
Total Liabilities 1.56 1.44 1.69 1.62 1.62
% of Assets 38% 52% 54% 43% 43%
Current Liabilities - Total 1.56 1.44 1.69 1.62 1.62
% of Assets 38% 52% 54% 43% 43%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 2.53 1.31 1.44 2.18 2.18
% of Assets 62% 48% 46% 57% 57%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.85) (1.83) (2.23) (2.67) (8.59)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 0.12 0.49 2.61 3.35 6.58

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference